Tyra Biosciences Reports Results for Quarter Ended June 30, 2026

What Happened

• Tyra Biosciences, Inc. (TYRA) filed a Current Report on Form 8-K on August 4, 2026 to announce its financial results for the quarter ended June 30, 2026.
• The company issued a press release with those results, which is attached to the 8-K as Exhibit 99.1 and incorporated by reference.

Key Details

• Filing date: August 4, 2026.
• Reporting item: Item 2.02 (Results of Operations and Financial Condition).
• Period covered: quarter ended June 30, 2026.
• Press release attached as Exhibit 99.1; the report was signed by CFO Alan Fuhrman.

Why It Matters

• The filing signals Tyra has publicly released its latest quarterly earnings and operational results; investors should review the attached press release for revenue, profit/loss, guidance, and operational updates.
• The 8-K notes the press release is furnished (not “filed”) under SEC rules, which affects certain legal liabilities — but the substance of the company’s disclosed results and commentary is what investors should use to assess near-term performance and expectations.
• After reviewing the press release, investors may want to watch for the company’s subsequent detailed filings (e.g., 10-Q) or investor calls for more complete financial statements and management discussion.